10-Q: Astrotech Q2 2025: Revenue Up, Net Loss Widens Amid R&D Focus

Astrotech Corporation reported increased revenue and reduced operating loss for Q2 2025, but net loss widened due to lower other income, while cash and investments declined.

Summary

• Total revenue for the six months ended December 31, 2025, increased by $150,000 to $445,000, up from $295,000 in the prior year period.
• Net loss for the six months ended December 31, 2025, was $(7,392,000), a slight increase from $(7,287,000) in the same period of 2024.
• Operating expenses decreased by $480,000, or 5.9%, to $7,633,000 for the six months ended December 31, 2025, primarily due to a $610,000 reduction in Research and Development expenses.
• Gross margin decreased to 44% for the six months ended December 31, 2025, from 56% in the prior year, as cost of revenue increased at a rate nearly proportional to revenue growth.
• Cash and cash equivalents stood at $3,095,000 as of December 31, 2025, a slight decrease from $3,100,000 at June 30, 2025.
• Short-term investments significantly decreased to $7,037,000 as of December 31, 2025, from $15,108,000 at June 30, 2025.
• Working capital decreased to $12,450,000 as of December 31, 2025, from $19,524,000 at June 30, 2025.
• The company's disclosure controls and procedures were deemed effective as of December 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to widening net losses, declining gross margin, and significant reduction in cash and investments, despite revenue growth and operational progress in specific segments. The explicit mention of needing potential equity offerings for future funding underscores liquidity concerns.

Positives

• Total revenue increased by $150,000 to $445,000 for the six months ended December 31, 2025, compared to $295,000 in the prior year.
• Loss from operations improved by $512,000, decreasing to $(7,437,000) for the six months ended December 31, 2025, from $(7,949,000) in the prior year.
• Operating expenses decreased by $480,000, or 5.9%, for the six months ended December 31, 2025, driven by a $610,000 reduction in Research and Development expenses.
• 1st Detect's TRACER 1000 ETD received TSA approval for the Air Cargo Security Technology List, advancing to Stage II testing.
• 1st Detect fulfilled a $429,000 purchase order for TRACER 1000 ETDs from a TSA-approved contractor, marking the first TSA-approved sale.
• AgLAB's field trials demonstrated that the AgLAB 1000-D2 Maximum Value Process solution can improve ending-weight yields by approximately 15% to 30% in hemp and cannabis distillation.
• The company formed a new subsidiary, EN-SCAN, on February 28, 2025, to develop environmental testing solutions using proprietary GC and AMS Technology.

Negatives

• Net loss for the six months ended December 31, 2025, increased to $(7,392,000) from $(7,287,000) in the prior year period.
• Gross margin decreased significantly to 44% for the six months ended December 31, 2025, from 56% in the prior year, due to increased cost of revenue.
• Short-term investments decreased by $8,071,000 from $15,108,000 at June 30, 2025, to $7,037,000 at December 31, 2025.
• Working capital decreased by $7,074,000 from $19,524,000 at June 30, 2025, to $12,450,000 at December 31, 2025.
• Net cash used in operating activities increased by $749,000 to $(7,479,000) for the six months ended December 31, 2025, compared to $(6,730,000) in the prior year.
• Other income and expense, net, decreased significantly by $617,000 for the six months ended December 31, 2025, primarily due to lower dividend income and higher realized loss on securities.
• BreathTech Corporation's pilot study with Cleveland Clinic terminated, and the company decided to deploy capital to other subsidiaries due to the long commercialization timeline and significant investment required for breath analysis applications.

Risks

• Adverse expectations regarding the global economy, inflation, potential for recession, and geopolitical tensions could impact the ability to sell products and services or gain customers.
• Product demand and market acceptance risks, including the ability to develop and sell products and services to governmental or commercial customers.
• Impact of trade barriers imposed by the U.S. government and potential corresponding actions by other countries.
• Technological difficulties and potential legal claims arising from any technological difficulties.
• Risks related to the availability of, and cost inflation in, supply chain inputs, including labor, raw materials, commodities, packaging, and transportation.
• Uncertainty in government funding and support for key programs, grant opportunities, or procurements.
• Impact of competition on the ability to win new contracts.
• Ability to meet technological development milestones and overcome development challenges.
• Ability to successfully identify, complete, and integrate acquisitions.
• Potential detrimental effects from changes in enforcement by federal or state governments regarding the evolving regulatory area of cannabis, despite not directly harvesting, manufacturing, distributing, or selling cannabis products.
• Customer concentration risk, with three major customers accounting for substantially all revenue for the three and six months ended December 31, 2025.
• Funds maintained in bank accounts may exceed FDIC insurance limits, posing a risk of loss for uninsured balances.
• The company may be required to obtain additional resources to successfully execute its business plans, and there is no assurance that additional capital can be raised on acceptable terms, which could impact the ability to continue as a going concern.
• Utilization of net operating loss (NOL) carryforwards is subject to annual limitation under Section 382 of the Internal Revenue Code if a greater than 50 percentage point aggregate change in ownership occurs over a three-year period.

Future Outlook

Management believes current available resources, combined with potential funds from equity offerings, will suffice for planned expenditures over the next 12 months, though no assurances are given for successful capital raising. The company continues to pursue TSA certification for the TRACER 1000 ETD and expects to enhance disclosures of expenses based on new accounting standards effective after December 15, 2026.

Management Comments

• Management believes that its current available resources, along with potential funds to be received from potential equity offerings, will be sufficient to fund the Company's planned expenditures over the next 12 months.
• Management recognizes that it may be required to obtain additional resources to successfully execute its business plans.
• No assurances can be given that management will be successful in raising additional capital, if needed, or on acceptable terms.
• Management does not believe any legal matters, individually or in aggregate, will have a material adverse effect on the Company's financial position or results of operations.

Industry Context

StockSavvy.ai notes that Astrotech's continued focus on specialized mass spectrometry applications, particularly in security (explosives/narcotics detection) and agriculture (cannabis distillation), positions it in niche but growing markets. The progress with TSA approval for the TRACER 1000 ETD is a critical step in penetrating the competitive U.S. airport security market, which is dominated by established players using IMS technology. The expansion into environmental testing with EN-SCAN also aligns with increasing global demand for real-time monitoring solutions. However, the significant R&D investment and ongoing net losses highlight the challenges of commercializing advanced technologies in capital-intensive sectors.

Comparison to Industry Standards

• The TRACER 1000's ECAC certification and TSA approval for air cargo (Stage II testing) positions it against incumbent ion mobility spectrometry (IMS) based ETDs from companies like Smiths Detection and L3Harris. Astrotech claims its MS-based technology offers higher resolution and fewer false alarms, addressing a key pain point for current ETD users.
• AgLAB's reported 15-30% yield improvement in cannabis distillation with the AgLAB 1000-D2 MVP suggests a competitive advantage in a fragmented and rapidly evolving cannabis processing market, where efficiency and potency are critical. Direct comparable companies are difficult to pinpoint without more specific market data, but this could differentiate AgLAB from standard laboratory testing equipment providers.
• The decision to de-emphasize BreathTech due to long commercialization timelines and significant investment aligns with industry realities for medical device development, which often faces extensive regulatory hurdles and lengthy clinical trial processes, contrasting with the faster market entry potential in security or agriculture applications.

Corporate Governance

Legal Proceedings

• The company is subject to legal and administrative proceedings, settlements, investigations, claims, and actions from time to time. Management does not believe any matters, individually or in aggregate, will have a material adverse effect on the company's financial position or results of operations.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, continued net losses impacting shareholder value, but potential upside from successful commercialization of new technologies.
• Employees: Continued investment in R&D and new subsidiaries (EN-SCAN) may indicate job stability or growth in specific areas, offset by strategic reallocation of capital from less promising ventures like BreathTech.
• Customers: Continued development and certification of products like TRACER 1000 (TSA approval) and AgLAB 1000-D2 (yield improvements) could lead to more effective and efficient solutions.
• Creditors: Declining working capital and reliance on future capital raises could increase perceived credit risk, though current cash and investments provide some buffer.

Next Steps

• Conduct field trials with the TSA for the TRACER 1000 ETD to advance to the qualified list.
• Undergo Developmental Test and Evaluation by the Transportation Security Laboratory (TSL) for TSA checkpoint testing of the TRACER 1000.
• Continue sales efforts for the AgLAB 1000-D2 in the hemp and cannabis markets.
• Explore how advancements and knowledge from BreathTech research can be applied in other existing and potential new business units.
• EN-SCAN to develop and manufacture a new line of instruments for environmental testing.
• Potentially raise capital through equity offerings as indicated by the effective S-3 registration statement.

Key Dates

Recommendation

While Astrotech shows promising technological advancements and revenue growth in certain segments, the widening net loss, declining gross margin, and significant reduction in cash and short-term investments raise concerns about its financial health and liquidity. The explicit mention of needing to raise additional capital and the effective S-3 registration statement indicate potential future dilution. However, the progress with TSA approval for 1st Detect and the formation of EN-SCAN offer long-term growth potential. A 'hold' recommendation is appropriate, advising investors to monitor the company's ability to secure additional funding and successfully commercialize its technologies, while acknowledging the significant risks.

Keywords

Mass Spectrometry, Explosives Trace Detection, Narcotics Trace Detection, Security Technology, Environmental Testing, Cannabis Distillation, Industrial Process Control, Breath Analysis, SEC Filing, Quarterly Report, ASTC, 1st Detect, AgLAB, EN-SCAN, Pro-Control, TRACER 1000, AgLAB 1000-D2, TSA Approval, ECAC Certification